In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SARcode Bioscience Inc.

Division of Takeda Pharmaceutical Co. Ltd.

Latest From SARcode Bioscience Inc.

EMA Unconvinced By Xiidra Dry Eye Data

The data package used to secure the US approval of Novartis's dry eye drug Xiidra (lifitegrast) was not enough to convince European regulators and experts in the field of eye diseases that the treatment should be sold in the EU.

Drug Review Ophthalmic

Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU

A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.

Ophthalmic Drug Review

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Novartis Delighted With Xiidra Deal Despite Eye-Watering Price

Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.

M & A Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • SARcode Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Quinton Oswald, CEO
    Todd Creech, CFO & VP, Bus. Dev.
    Charles Semba, MD, CMO
  • Contact Info
  • SARcode Bioscience Inc.
    Phone: (650) 416-7560
    100 Marina Blvd.
    Ste 250
    Brisbane, CA 94005